Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31413813 | 0.81 | PTGDR2 (0.47) | PTGDR2MAPTUSP2ALDH1A1TRPV4 | |
| SCHEMBL3167383 | 0.81 | PTGDR2 (0.47) | PTGDR2MAPTUSP2ALDH1A1TRPV4 | |
| SCHEMBL16855808 | 0.81 | MAPT (0.49) | PTGDR2MAPTUSP2ALDH1A1GAA | |
| SCHEMBL16834602 | 0.80 | MAPT (0.48) | PTGDR2MAPTUSP2SMN1; SMN2VNN1 | |
| SCHEMBL7634010 | 0.79 | TRPV4 (0.56) | PTGDR2MAPTALDH1A1TRPV4MGLL | |
| SCHEMBL2527854 | 0.76 | TRPV4 (0.40) | PTGDR2TRPV4MGLL | |
| SCHEMBL22781839 | 0.76 | CYP19A1 (0.43) | PTGDR2MAPTALDH1A1TRPV4MGLL | |
| SCHEMBL19584786 | 0.76 | PTGDR2 (0.49) | PTGDR2ALDH1A1SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL18397132 | 0.76 | TRPV4 (0.47) | PTGDR2ALDH1A1TRPV4 | |
| SCHEMBL3365987 | 0.76 | SLC6A4 (0.56) | PTGDR2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373162-B1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-8168681-B2 | Amidoacetonitrile compounds and pesticidal composition thereof | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NAAA, PTMS, NIT2 | PTGDR2 3228/4885MAPT 2576/4885USP2 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.